Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027

Artiva Biotherapeutics, Inc.

Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.
AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.
Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.
Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.